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Carbamazepine inhibits angiotensin I-converting
enzyme, linking it to the pathogenesis of temporal
lobe epilepsy
SS Almeida1, MG Naffah-Mazzacoratti2, PB Guimara˜es1, F Wasinski1, FEG Pereira1, M Canzian3, RS Centeno3, H Carrete3,
EM Yacubian3, AK Carmona1, RFF Vieira1, CR Nakaie1, RA Sabatini1, SR Perosa2, RFP Bacurau4, TLF Gouveia2, G Gallo5,
M Wu¨rtele5, EA Cavalheiro2, JA Silva Jr6, JB Pesquero1 and RC Araujo1
We find that a common mutation that increases angiotensin I-converting enzyme activity occurs with higher frequency in male
patients suffering from refractory temporal lobe epilepsy. However, in their brains, the activity of the enzyme is downregulated.
As an explanation, we surprisingly find that carbamazepine, commonly used to treat epilepsy, is an inhibitor of the enzyme, thus
providing a direct link between epilepsy and the renin–angiotensin and kallikrein–kinin systems.
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Introduction
Epilepsy is a chronic neurological disease characterized by
abnormal neural activity leading to epileptic seizures afflicting
B1% of the population worldwide. We have recently found
that temporal lobe epilepsy (TLE) patients show increased
expression of the Angiotensin II (Ang II) AT1 and AT2
receptors1 as well as the kinin B1 and B2 receptors in their
brain,2 thus providing a link between one of the most common
forms of epilepsy, TLE associated to mesial sclerosis, to the
so-called renin–angiotensin (RAS) and kallikrein–kinin sys-
tems (KKS).1,2 These systems, associated with regulation of
blood pressure and several functions in the central nervous
system,1 consist of a series of regulatory proteolytic steps,
including conversion of angiotensinogen by renin to angio-
tensin I (Ang I), which is further degraded by angiotensin I-
converting enzyme (ACE) to Ang II and conversion of
kininogen by kallikrein to the peptide bradykinin, which in turn
can be degraded by ACE.3
Because of its dual function as an angiotensin processing
and kinin degrading enzyme, we therefore undertook the task
to examine patients suffering from epilepsy for the occurrence
of the common ACE insertion (I)/deletion (D) polymorphism,
where the introduction of a 287-bp Alu-repeat sequence into
intron 16 of the ACE gene has been shown to induce lower
ACE plasma activities in the carriers of this mutation.4,5
Our surprising finding in this report that a majority of
patients suffering from severe forms of epilepsy belong
to the DD genotype, led us to postulate that distinct activities
of this enzyme (levels of angiotensin/kinins) might be
involved in TLE. Aiming to corroborate these results, we then
tested directly the hypothesis that polypharmacological
effects of current available drugs could have effects
mediated by ACE inhibition, leading to the finding that
carbamazepine, one of the most commonly used drugs in
the treatment of epilepsy and psychiatric disorders is a direct
inhibitor of ACE.
Methods
Genotyping. The ACE I/D polymorphism was genotyped as
described6 in 72 patients with epilepsy who underwent surgery
and 368 controls. All subjects abstained from alcohol and
caffeine intake for at least 24h before the blood tests. Smokers
and subjects who had received antihypertensive drugs were
excluded from the control group. Each subject gave informed
consent before collection of DNA at the beginning of the
experimental procedure. The genotypes of all experimental
groups are shown in Supplementary Table 1.
Surgical procedures. Surgical specimens from patients with
intractable epilepsy were submitted to standard corticoamyg-
dalohippocampectomy at the Sa˜o Paulo Hospital (Epilepsy
Research and Treatment Unit, UNIPETE, Sa˜o Paulo, Brazil) for
seizure control. All cases showing neoplasm, vascular malfor-
mations, post-traumatic and ischemic lesion in preoperative
magnetic resonance imaging (MRI) were excluded. Selected
patients (n¼ 9) had detailed anamnesis, video electroencephalo-
gram recordings, and MRI studies. Antiepileptic drugs used by
these patients for seizure control included: carbamazepine,
phenobarbital, valproic acid and phenytoin. Surgery was
performed at least 48h after the last seizure. The outcome of
seizures after epilepsy surgery was classified according to
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Engel’s four categories.7 Control tissues were obtained from
autopsies (less than 5h post mortem) (n¼ 9) from brains
showing no evidence of pathology based on a gross
classification after routine histological examination, and were
obtained from autopsies carried out by a pathologist
trained especially for this purpose from the Anatomical
Pathology Department (INCOR, FMUSP). By using this
procedure, similar hippocampal areas from epileptic patients
and autopsied subjects could be compared. Hippocampi were
dissected, frozen in liquid nitrogen and stored at 80 1C. All
experiments were performed under approval from the
Institutional Ethics Committee of the Federal University of Sa˜o
Paulo (UNIFESP).
ACE activity assays. Somatic ACE activity from human
hippocampi was assayed using a fluorescence resonance
energy transfer substrate containing ortho-aminobenzoic
(Abz) and dinitrophenyl (Dnp) as fluorescence donor/
acceptor pair, namely Abz-FRK(Dnp)P-OH, as described.8
ACE specific activity for each tissue was calculated by
division of velocity values in mMmin1 by the respective
protein concentrations, as determined by the Bradford
method (Bio-Rad Laboratories, Hercules, CA, USA).
Activity of purified, or plasma ACE (control n¼ 127; TLE
n¼ 43) was measured in the same way but normalized
either by the enzyme amount or plasma volume, respec-
tively. In the cellular assays, Chinese hamster ovary cells
(CHO) were transfected with human ACE and its activity
evaluated either with the fluorescence resonance energy
transfer substrate Abz–FRK(Dnp)P–OH, as described,9 or
with the endogenous substrate Ang I as assayed by high-
performance liquid chromatography (HPLC). Measurements
were done in triplicate and ACE activity was reported as mM
of Abz-FRK(Dnp)P-OH hydrolyzed per minute of substrate
hydrolyzed after 6min of incubation in the presence of
different concentrations of carbamazepine. For the deter-
mination of the inhibitory effect of carbamazepine on ACE
hydrolytic activity with Ang I, samples were preincubated for
2 h with different concentrations of carbamazepine. Samples
were then incubated in the same buffer with 10 mM of Ang I
(Sigma-Aldrich, St Louis, MO, USA), in the presence or
absence of 2.5 mM of lisinopril. Supernatant aliquots (400 ml)
were collected after 0, 2, 5, 15 and 30min, and the reaction
was stopped by the addition of 2 ml 10% trifluoroacetic acid
(TFA). The conversion of Ang I to Ang II was determined by
HPLC analysis using a Vydac C18 (4.6 150mm) column
equilibrated with solvent A (0.1% TFA/H2O) and eluted with
solvent B (0.1% TFA; 60% acetonitrile/H2O) with a 30–45%
acetonitrile gradient of solvent B for 15min, with a flow of
1.5mlmin1 and detection at 220 nm wavelength. Some
peaks were collected and analyzed in an automatic amino-
acid sequencer to confirm their sequence (data not shown).
Measurements were made in duplicate and the values of
ACE activity were shown as percentage of basal Ang I
degradation per minute per milligram of total protein
(%min1mg1).
Kallikrein assay. Assays were performed using purified
enzyme (0.57mgml1; Enzyme Research Laboratories,
South Bend, IN, USA) in 50mM Tris-HCL buffer (pH 7.4)
using the fluorogenic substrate Z-Phe-Arg-AMC as
described.6
Animal model. C57Bl/6 mice were obtained from the Center
for the Development of Experimental Models for Medicine
and Biology (CEDEME) at the Federal University of Sa˜o
Paulo and were kept at 22 1C in a light–dark cycle (12 in
12 h), with ad libitum supply of water and standard rodent
chow. Carbamazepine was administered in mice by gavage,
at a dose of 150mg kg1. After 60min, animals were killed by
cervical dislocation for blood collection; plasma was extracted
by centrifugation and stored at –801C. All experiments were
conducted in accordance with the NIH guide for care of
laboratory animals and their uses (Institute of Laboratory
Animal Resources, National Academy Press, Washington DC,
1996) after approval by the Ethics Committee in Research of
UNIFESP.
Statistics. All data are given as mean±s.e.m. Statistical
evaluations were performed using Student’s t-test for
unpaired data or one-way analysis of variance followed
by the Tukey’s post-hoc test to identify significant data
points. Genotype frequencies observed in our cohort were in
Hardy–Weinberg equilibrium. Results were considered signi-
ficant with Po0.05.
Results and Discussion
Owing to the association between ACE and epilepsy, we
examined male patients suffering from refractory TLE for the
occurrence of the common ACE insertion (I)/deletion (D)
polymorphism, which is known to induce lower ACE plasma
activities in II subjects.4 Surprisingly, we found a significant
higher number of patients suffering from TLE with the DD
genotype (46%) when compared with the normal subjects
(27%; Figures 1a–d). Concomitantly, TLE patients of both
sexes with the II genotype, that express less ACE, showed a
significantly better recovery rate after corticoamygdalohippo-
campectomies (Figure 1e). As the D form leads to higher
expression levels of ACE, we expected to be able to measure
higher ACE activities in the plasma of male patients suffering
from TLE. ACE activity was indeed significantly elevated in
subjects with the DD genotype of the control group. However,
we could only detect a non-significant trend to higher ACE
activities in patients suffering from TLE with the DD genotype
(Figures 1f and g). Furthermore, when we examined ACE
activity in the hippocampus from seizure-control corticoamyg-
dalohippocampectomies, we detected a twofold lower ACE
activity in these patients (Figure 1h).
As these results seemed contradictory, we therefore
hypothesized that if higher ACE expression is casually
involved in the pathogenesis of TLE, perhaps its treatment
could be linked to a reduction of ACE activity. Consequently,
we decided to screen biochemically for the effects on ACE
activity of different drugs commonly used to treat epilepsy. All
the drugs tested showed insignificant changes in ACE activity,
except carbamazepine, which significantly inhibited ACE
activity in a dose-dependent manner (Figure 2a). Carbama-
zepine is normally used to treat TLE in doses of 400–1200mg
per day,9 where the minimal dose (400mg per day) is
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equivalent to a concentration of 0.34mM in the blood. At this
level, carbamazepine was able to inhibit B25% the plasma
activity of human ACE (Figure 2a).
To exclude artifacts from other proteases present in blood
plasma, we repeated this experiment using purified ACE
corroborating our results (Figure 2b). Inhibition of ACE by
carbamazepine was additionally confirmed in a dose-depen-
dent manner using HPLC to identify direct degradation of the
native Ang I peptide by the enzyme produced in ACE-
transfected CHO. Carbamazepine was able to inhibit
B75% of ACE at the cellular level (Figure 2c, Supplementary
Figure 1). Taken together all these independent experiments
indicate in vitro direct inhibition of ACE by carbamazepine at
concentrations similar to those used by TLE patients. To
analyze the action of carbamazepine in vivo, we fed mice
with a dose of 150mg per kg of carbamazepine. The mice
were killed after 60min, and their serum analyzed for ACE
activity. Again in this experiment we could confirm B25%
inhibition of ACE activity by carbamazepine (Figure 2d).
Finally, direct inhibition of ACE by carbamazepine was
additionally confirmed by comparing treated with non-
carbamazepine-treated TLE patients. In this experiment,
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Figure 1 ACE activity and TLE. (a, b) Distributions of the I/D ACE polymorphism in the control and TLE group (control n¼ 368; TLE n¼ 72). (c, d) Allele frequencies.
(e) Percentage of class 1A (best) outcome (Engel’s classification7) depending on genotype. (f, g) Mean (±s.e.m.) soluble ACE activity according to I/D distribution in
the control group (n¼ 127) and in patients with TLE (n¼ 43). (h) Hippocampal tissue ACE activity. *Po 0.05, **Po0.01, ***Po0.001.
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treatment with carbamazepine led to a similar ACE activity as
in the control group, whereas non-carbamazepine-treated
TLE patients had a higher ACE activity (Figure 2e). However,
we did not observe blood pressure differences between the
treated TLE and non-treated TLE groups (Supplementary
Table 2).
All components of the RAS and KKS have been found in the
brain10 modulating functions such as stress, anxiety, learning
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Figure 2 Inhibition of ACE by carbamazepine. (a) Inhibitory profile of different drugs used in the treatment of epilepsy. Carbamazepine was the only antiepileptic drug able
to inhibit plasmatic ACE activity. (b) Enzymatic activity of purified ACE. Mean (±s.e.m.) (*Po0.05, ***Po0.001). As a non-specificity control, carbamazepine had no
inhibitory effect on either human plasmatic or purified kallikrein (Supplementary Figure 2). (c) HPLC assay demonstrating carbamazepine inhibition of Ang I degradation by
ACE (***Po 0.001). (d) Mean (±s.e.m.) plasmatic ACE activity is decreased 60 min after carbamazepine administration by gavage (150mg kg1) in mice (**Po0.01).
(e) Mean (±s.e.m.) plasmatic ACE activity of TLE patients treated with carbamazepine (n¼ 35) resembles that of the control group (n¼ 55), whereas non-carbamazepine-
treated TLE patients (n¼ 15) have significantly higher ACE activities (*Po0.05).
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and memory acquisition.11 Under pathological conditions the
RAS promotes inflammatory responses increasing neural
excitability,12 glial scar formation and transformation of a
normal neural network into a seizure-generating network, thus
providing a basis for a linkage between angiotensin signaling
and epilepsy.13 Our results provide further evidence for this
hypothesis, as we find a higher proportion of TLE patients with
the DD ACE polymorphism phenotype, which leads to higher
ACE activity levels of the enzyme. Furthermore we surpris-
ingly find that carbamazepine is an inhibitor of ACE in the
concentration range used to treat patients.
It has been recently reported that TLE patients show
increased expression of the Ang II AT1 and AT2 receptors1 as
well as the kinin B1 and B2 receptors in the hippocampus2 and
that captopril, a classical ACE inhibitor, enhances the anti-
convulsant activity of carbamazepine.14 These results indeed
strengthen the case for a link between the RAS and KKS and
the pathogenesis of epilepsy. Furthermore, as carbamaze-
pine is thought to display anticonvulsant activity due to its
inhibition of sodium channels,9 our results enrich once again
the list of known drugs with polypharmacological effects.
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